Suppr超能文献

一项针对常染色体显性遗传性高血压并指患者的交叉药物试验。

A cross-over medication trial for patients with autosomal-dominant hypertension with brachydactyly.

作者信息

Schuster H, Toka O, Toka H R, Busjahn A, Oztekin O, Wienker T F, Bilginturan N, Bähring S, Skrabal F, Haller H, Luft F C

机构信息

Franz Volhard Clinic, Virchow Klinikum, Humboldt University of Berlin, Germany.

出版信息

Kidney Int. 1998 Jan;53(1):167-72. doi: 10.1046/j.1523-1755.1998.00732.x.

Abstract

We examined a family with autosomal-dominant hypertension and brachydactyly from northeastern Turkey. The hypertension was defined as severe, resulting in stroke before age 50 years, featuring normal renin, aldosterone, and catecholamine responses, and did not appear to be salt-sensitive. The responsible gene resides on chromosome 12p. To determine which medications were most effective, we performed a prospective clinical trial. We studied 13 affected individuals in a randomized double-blind, cross-over trial including a beta-blocker (BBL), alpha-blocker (ABL), calcium channel blocker (CCB), converting enzyme inhibitor (CEI), and hydrochlorothiazide (HCT) and placebo (PLA). We then added moxonidine (MOX) and continued the trial for an additional period in a single-blind fashion. Each drug was given for four weeks with an option to double the dose after two weeks; each washout period comprised two weeks. Blood, 24-hour urine, and saliva were studied at the outset, and blood and urine samples were obtained at the end of each phase. Blood pressure (BP) and heart rate measurements were with the patient ambulatory at 24 hours. All regimens required doubled doses at two weeks. Beta blocker, CCB, CEI, and ABL lowered BP (6 to 10 mm Hg) and BP load compared to PLA, while HCT and MOX did not. Converting enzyme inhibitor and HCT increased plasma renin activity (PRA), while BBL lowered PRA. The 24-hour urine analysis indicated a high dietary salt intake with a low potassium and calcium intake. The salivary electrolytes showed similar sodium and potassium concentrations, while chloride values were significantly higher in affected than nonaffected subjects. Thus, this monogenic form of hypertension resembles nonsalt-sensitive essential hypertension in that BBL, CCB, CEI, and ABL were effective, while HCT was not. The BP reduction was similar to other single drug trials in essential hypertension. The high salivary chloride values suggest an additional intermediary phenotype that may be related to electrolyte transport. These results raise the possibility that an as yet unknown hypertensive mechanism is operative in these subjects.

摘要

我们对来自土耳其东北部的一个患常染色体显性遗传性高血压并伴有短指畸形的家族进行了研究。该高血压被定义为重度,导致患者在50岁之前发生中风,其肾素、醛固酮和儿茶酚胺反应正常,且似乎对盐不敏感。致病基因位于12号染色体短臂上。为确定哪种药物最为有效,我们开展了一项前瞻性临床试验。我们在一项随机双盲交叉试验中研究了13名患病个体,该试验包括使用一种β受体阻滞剂(BBL)、一种α受体阻滞剂(ABL)、一种钙通道阻滞剂(CCB)、一种转换酶抑制剂(CEI)、氢氯噻嗪(HCT)以及安慰剂(PLA)。随后我们添加了莫索尼定(MOX),并以单盲方式继续试验一段时间。每种药物服用四周,两周后可选择将剂量加倍;每个洗脱期为两周。在试验开始时对血液、24小时尿液和唾液进行了研究,并在每个阶段结束时采集血液和尿液样本。血压(BP)和心率测量是在患者24小时动态状态下进行的。所有治疗方案在两周时都需要加倍剂量。与安慰剂相比,β受体阻滞剂、钙通道阻滞剂、转换酶抑制剂和α受体阻滞剂降低了血压(6至10毫米汞柱)和血压负荷,而氢氯噻嗪和莫索尼定则没有。转换酶抑制剂和氢氯噻嗪增加了血浆肾素活性(PRA),而β受体阻滞剂降低了PRA。24小时尿液分析表明饮食中盐摄入量高,而钾和钙摄入量低。唾液电解质显示钠和钾浓度相似,而患病个体的氯值明显高于未患病个体。因此,这种单基因形式的高血压与非盐敏感性原发性高血压相似,即β受体阻滞剂、钙通道阻滞剂、转换酶抑制剂和α受体阻滞剂有效,而氢氯噻嗪无效。血压降低情况与原发性高血压的其他单药试验相似。唾液中高氯值表明可能存在一种与电解质转运有关的额外中间表型。这些结果增加了一种尚未知晓的高血压机制在这些受试者中起作用的可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验